TIMES OF ISRAEL
Japan turns to Israeli tech to treat radiation disease
by David Shamah
December 4, 2015

Four years after Japan’s Fukushima nuclear plant disaster, the country is still not out of the woods, with the risk of mass radiation poisoning a continued risk. That is why the Fukushima Medical University’s Global Medical Science Center has signed a deal with Israel’s Pluristem Therapeutics to further develop the company’s PLX-R18 cells to treat acute radiation syndrome (ARS). Under the deal, PLX-R18 cells will be studied primarily as a potential treatment for radiation-induced damage to the skin, lungs and gastrointestinal tract…Enter Pluristem, a Haifa-based company that is developing a cure for acute radiation syndrome (ARS), also known as radiation disease, the mass destruction of tissues and cells caused by exposure to extremely high levels of radiation, such as a nuclear catastrophe. READ MORE